These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 8093573

  • 21. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
    Hansard MJ, Smith LA, Jackson MJ, Cheetham SC, Jenner P.
    Mov Disord; 2004 Jan; 19(1):15-21. PubMed ID: 14743355
    [Abstract] [Full Text] [Related]

  • 22. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
    Pearce RK, Jackson M, Smith L, Jenner P, Marsden CD.
    Mov Disord; 1995 Nov; 10(6):731-40. PubMed ID: 8749992
    [Abstract] [Full Text] [Related]

  • 23. Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors.
    Guigoni C, Aubert I, Li Q, Gurevich VV, Benovic JL, Ferry S, Mach U, Stark H, Leriche L, Håkansson K, Bioulac BH, Gross CE, Sokoloff P, Fisone G, Gurevich EV, Bloch B, Bezard E.
    Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S25-9. PubMed ID: 15885624
    [Abstract] [Full Text] [Related]

  • 24. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys.
    Blanchet PJ, Konitsiotis S, Chase TN.
    Mov Disord; 1998 Sep; 13(5):798-802. PubMed ID: 9756148
    [Abstract] [Full Text] [Related]

  • 25. Selective D2 receptor stimulation induces dyskinesia in parkinsonian monkeys.
    Luquin MR, Laguna J, Obeso JA.
    Ann Neurol; 1992 May; 31(5):551-4. PubMed ID: 1350718
    [Abstract] [Full Text] [Related]

  • 26. Effects of the nicotinic acetylcholine receptor agonist SIB-1508Y on object retrieval performance in MPTP-treated monkeys: comparison with levodopa treatment.
    Schneider JS, Van Velson M, Menzaghi F, Lloyd GK.
    Ann Neurol; 1998 Mar; 43(3):311-7. PubMed ID: 9506547
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism.
    Graham WC, Sambrook MA, Crossman AR.
    Brain Res; 1993 Feb 05; 602(2):290-303. PubMed ID: 8095431
    [Abstract] [Full Text] [Related]

  • 31. Dopamine D1 and D2 receptor interactions in the MPTP-treated marmoset.
    Elliott PJ, Walsh DM, Close SP.
    Neurosci Lett; 1992 Aug 03; 142(1):1-4. PubMed ID: 1357609
    [Abstract] [Full Text] [Related]

  • 32. Neurotensin receptors and dopamine transporters: effects of MPTP lesioning and chronic dopaminergic treatments in monkeys.
    Goulet M, Morissette M, Grondin R, Falardeau P, Bédard PJ, Rostène W, Di Paolo T.
    Synapse; 1999 Jun 01; 32(3):153-64. PubMed ID: 10340626
    [Abstract] [Full Text] [Related]

  • 33. Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
    Fox SH, Henry B, Hill M, Crossman A, Brotchie J.
    Mov Disord; 2002 Nov 01; 17(6):1180-7. PubMed ID: 12465055
    [Abstract] [Full Text] [Related]

  • 34. Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin.
    Morissette M, Dridi M, Calon F, Hadj Tahar A, Meltzer LT, Bédard PJ, Di Paolo T.
    Mov Disord; 2006 Jan 01; 21(1):9-17. PubMed ID: 16127720
    [Abstract] [Full Text] [Related]

  • 35. Effect of D1 receptor stimulation in normal and MPTP monkeys.
    Bédard PJ, Boucher R.
    Neurosci Lett; 1989 Sep 25; 104(1-2):223-8. PubMed ID: 2573015
    [Abstract] [Full Text] [Related]

  • 36. Chronic CY 208-243 treatment of MPTP-monkeys causes regional changes of dopamine and GABAA receptors.
    Gagnon C, Gomez-Mancilla B, Bédard PJ, Di Paolo T.
    Neurosci Lett; 1993 Nov 26; 163(1):31-5. PubMed ID: 7905197
    [Abstract] [Full Text] [Related]

  • 37. Clinical pharmacology of levodopa-induced dyskinesia in parkinsonian patients.
    Rascol O, Brefel-Courbon C, Descombes S, Montastruc JL.
    Adv Neurol; 1999 Nov 26; 80():485-90. PubMed ID: 10410760
    [No Abstract] [Full Text] [Related]

  • 38. Levodopa but not ropinirole induces an internalization of D1 dopamine receptors in parkinsonian rats.
    Muriel MP, Orieux G, Hirsch EC.
    Mov Disord; 2002 Nov 26; 17(6):1174-9. PubMed ID: 12465054
    [Abstract] [Full Text] [Related]

  • 39. 125I-CGP 64213 binding to GABA(B) receptors in the brain of monkeys: effect of MPTP and dopaminomimetic treatments.
    Calon F, Morissette M, Goulet M, Grondin R, Blanchet PJ, Bédard PJ, Di Paolo T.
    Exp Neurol; 2000 May 26; 163(1):191-9. PubMed ID: 10785458
    [Abstract] [Full Text] [Related]

  • 40. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disability.
    Iravani MM, Tayarani-Binazir K, Chu WB, Jackson MJ, Jenner P.
    J Pharmacol Exp Ther; 2006 Dec 26; 319(3):1225-34. PubMed ID: 16959959
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.